Abstracts tagged "SLE and tacrolimus"

Abstract Number: 678 • 2014 ACR/ARHP Annual Meeting
The Effectiveness of Tacrolimus for Minor Flares of the Patients with Systemic Lupus Erythematosus
Haruki Watanabe¹, Ryutaro Yamanaka², Ken-ei Sada³, Eri Katsuyama¹, Takayuki Katsuyama³, Mariko Narazaki³, Noriko Tatebe¹, Koichi Sugiyama¹, Katsue S. Watanabe³, Hiroshi Wakabayashi¹, Tomoko Kawabata¹, Jun Wada³ and Hirofumi Makino³, ¹Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ²Internal Medicine, Himeji Red Cross Hospital, Himeji, Japan, ³Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Background/Purpose Although effectiveness of tacrolimus (TAC) for remission induction or maintenance treatment of patients with lupus nephritis has been reported, there are few reports about…
Abstract Number: 1570 • 2013 ACR/ARHP Annual Meeting
Maintenance Therapy With Taclorimus and Mizoribine Pulse In SLE
Hiroshi Kajiyama¹, Daisuke Ikuma¹, Muneo Ota², Yuki Shimada¹, Kazuhiro Yokota³, Yasuto Araki¹, Kojiro Sato¹, Yu F. Asanuma¹, Yuji Akiyama¹ and Toshihide Mimura⁴, ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ⁴Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan
Background/Purpose: It was reported in 2008 that multitarget therapy, consisting of taclorimus (TAC), mycophenolate mofetil (MMF) and glucocorticoid, is effictive and safe in induction therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].